VA
DNTH icon

VR Adviser’s Dianthus Therapeutics DNTH Stock Holding History

VR Adviser’s Portfolio DNTH Stock Details DNTH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$99M Buy
1,180,000
+180,000
+18% +$10.4M 3.7% 6
2025
Q4 		$41.2M Buy
1,000,000
+39,197
+4% +$1.52M 2.04% 17
2025
Q3 		$37.8M Sell
960,803
-39,197
-4% -$1M 2.13% 16
2025
Q2 		$18.6M Sell
1,000,000
-744,373
-43% -$14M 1.4% 20
2025
Q1 		$31.6M Hold
1,744,373
– – 2.69% 12
2024
Q4 		$38M Hold
1,744,373
– – 2.61% 13
2024
Q3 		$47.8M Sell
1,744,373
-350,000
-17% -$9.75M 2.5% 12
2024
Q2 		$54.2M Hold
2,094,373
– – 3.45% 10
2024
Q1 		$62.8M Buy
2,094,373
+1,166,667
+126% +$25.4M 2.99% 10
2023
Q4 		$9.65M Hold
927,706
– – 0.66% 28
2023
Q3 		$12.7M Buy
+927,706
New +$11.7M 1.34% 24

Other funds holding DNTH

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

VR Adviser's DNTH Position: Q1 2026 in Review

VR Adviser increased its Dianthus Therapeutics (DNTH) stake by 18% in Q1 2026, buying an estimated $10.4M and bringing the position to 1,180,000 shares worth $99M. The position accounts for 3.7% of the portfolio, ranked #6.

VR Adviser first reported a position in DNTH in Q3 2023 and has held it in 11 quarters since. 241 funds tracked by Wall St. Rank hold DNTH as of Q1 2026.

  • VR Adviser held 1,180,000 shares of Dianthus Therapeutics worth $99M as of Q1 2026.
  • VR Adviser bought 180,000 Dianthus Therapeutics shares in Q1 2026, an estimated $10.4M.
  • Dianthus Therapeutics made up 3.7% of VR Adviser's portfolio in Q1 2026, its #6 holding.
  • VR Adviser first reported a position in Dianthus Therapeutics in Q3 2023 and has held it in 11 quarters since.
  • 241 funds tracked by Wall St. Rank held Dianthus Therapeutics as of Q1 2026.

Based on VR Adviser's 13F filing for Q1 2026, filed 15 May 2026.